Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
Tuesday, July 14, 2020 8:02:07 AM
Remdesivir appears to be effective in treating hospitalized patients with COVID-19. But there's another big COVID-19 opportunity for Gilead that you'll really want to watch.
Gold coronavirus
IMAGE SOURCE: GETTY IMAGES.
Breathe in
Thus far, Gilead's primary focus has been on an intravenous form of remdesivir. However, the company announced on July 8 that it had initiated a phase 1a clinical study evaluating an inhaled solution of remdesivir. This study will enroll around 60 healthy participants between the ages of 18 and 45.
Does the big biotech think that the drug could prevent COVID-19 since its latest study involved healthy individuals? No. Instead, Gilead plans to use healthy participants to assess the safety, tolerability, and pharmacokinetics (movement of drugs in the body) of the inhaled version of remdesivir. If all goes well, Gilead plans to conduct additional clinical studies of the inhaled version of remdesivir in treating patients with COVID-19 who haven't been hospitalized.
The upper respiratory tract ranks as the main infection hot spot for patients with early stages of COVID-19. Gilead suspects that using a nebulizer to deliver an inhaled solution of remdesivir could be effective in helping these patients recover more quickly. Gilead chief medical officer Merdad Parsey stated that the promising clinical data for intravenous remdesivir in treating hospitalized patients made it "clear that efforts were needed to investigate the drug's potential in the outpatient setting."
A lucrative potential opportunity
SVB Leerink analyst Geoffrey Porges estimated that Gilead could make between $6 billion and $7 billion annually from remdesivir in the hospital setting. His projection, though, was based on the company pricing the drug at $5,000 per course in the U.S.
Gilead later announced a price tag of $2,340 per patient for a five-day treatment course of intravenous remdesivir. This pricing implies that the biotech could generate sales for the drug in the ballpark of $3 billion annually if Porges' calculations are on track.
But the outpatient market for an inhaled version of remdesivir would undoubtedly be much larger. In the U.S., a little over 52,500 individuals have been hospitalized for COVID-19 so far compared to around 3.3 million positive cases of COVID-19.
Quick calculations might lead you to believe that Gilead's opportunity in the outpatient setting could be more than 60 times greater than its hospital setting opportunity. Could an inhaled formulation of remdesivir open up a $180 billion or more market for the biotech? That's almost certainly way too optimistic. Many patients with positive COVID-19 tests have no symptoms and require no treatment.
Still, it doesn't seem unrealistic that an inhaled version of remdesivir could generate sales that rival or surpass Gilead's blockbuster HIV drugs that are already on the market. The company's best-selling drug, Biktarvy, should generate in the ballpark of $7 billion in sales this year.
Don't count the money yet
You shouldn't start counting Gilead's money for inhaled remdesivir just yet. The odds of any infectious-disease drug in a phase 1 study going on to win FDA approval are less 20%, according to historical data compiled by biopharmaceutical industry organization BIO.
For that matter, you probably shouldn't count on the IV version of remdesivir becoming a long-term commercial success for Gilead. It's possible that the emergence of vaccines and herd immunity could one day greatly reduce the need for COVID-19 treatments.
The good news for investors is that the biotech stock has other potential catalysts, notably including the anticipated U.S. and European approvals for filgotinib in treating rheumatoid arthritis. But you'll definitely want to monitor Gilead's progress with its early stage clinical study. The opportunity for an inhaled version of remdesivir is nothing to sniff at.
Recent GILD News
- Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains • IH Market News • 06/21/2024 12:00:38 PM
- Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention • Business Wire • 06/20/2024 12:51:00 PM
- Goldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and More • IH Market News • 06/17/2024 10:49:12 AM
- New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment • Business Wire • 06/14/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:23:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:20:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:18:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:15:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:12:00 PM
- Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA • Business Wire • 06/06/2024 08:30:00 AM
- Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis • Business Wire • 06/05/2024 06:00:00 AM
- Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia • Business Wire • 06/03/2024 02:00:00 PM
- Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma • Business Wire • 06/03/2024 01:00:00 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 • Business Wire • 05/31/2024 12:07:00 PM
- Gilead Provides Update on Phase 3 TROPiCS-04 Study • Business Wire • 05/30/2024 08:45:00 PM
- Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 • Business Wire • 05/22/2024 12:30:00 PM
- Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis • Business Wire • 05/18/2024 12:30:00 PM
- Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy • Business Wire • 05/14/2024 02:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:57:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:30:52 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM